ML-239 is an inhibitor of cancer stem cells, displaying greater than 23-fold selective inhibition of a breast cancer stem cell-like cell line (EC50 = 1.18 μM) over an isogenic control cell line (EC50 = 27.6 μM). It is also toxic to the breast carcinoma cell line MDA-MB-231. ML-239 alters the expression of genes in the MAPK, NF-κB, and inflammatory cytokine pathways. It is stable in saline and modestly stable in human plasma.
ML-239, is an inhibitor of breast cancer stem cells, with greater than 23 fold selectivity of inhibition in the cell line.
ChEBI: N'-(2-pyrrolylidenemethyl)-2-(2,4,6-trichlorophenoxy)acetohydrazide is an aromatic ether.
1) Carmody et al. (2012), Phenotypic high-throughput screening elucidates target pathway in breast cancer stem cell-like cells; J. Biomol. Screening, 17 1204
2) Germain et al. (2012), Identification of a selective small molecule inhibitor of breast cancer stem cells; Bioorg. Med. Chem., 22 3571
3) Rees et al. (2015), Correlating chemical sensitivity and basal gene expression reveals mechanism of action; Nat. Chem. Biol. 12 109
